Teneligliptin

DB11950InvestigationalSmall molecule

Teneligliptin has been investigated for the treatment of Type 2 Diabetes Mellitus.

Chemical structure of Teneligliptin
Mechanism
Curator reviewed
Formula / weight
C22H30N6OS · 426.578 g/mol (avg)
Code names
MP-513

Resolves to

Compound
UNII28ZHI4CF9CCAS760937-92-6ChEMBLCHEMBL2147777ChEBI136042PubChem11949652
Clinical / RWD
ATCA10BD28ATCA10BH08
Structure
InChIKeyWGRQANOPCQRCME-PMACEKPBSA-NSMILES[H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCSC1)N1CCN(CC1)C1=CC(C)=NN1C1=CC=CC=C1
Targets
P27487DPP4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
656Drug interactionsStructured to mechanism, not free text
Sign in
10Clinical trialsPhase, status and sponsor resolved per trial
Sign in
7Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
2ATC codesIncluding every combination product, plus 7 drug categories
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Teneligliptin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In